Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
about
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersAn allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaineAllostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapesA subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviorsA selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learningDiscovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.Novel Allosteric Modulators of G Protein-coupled ReceptorsCharacterization of an mGluR2/3 negative allosteric modulator in rodent models of depressionThe antipsychotic potential of muscarinic allosteric modulationAllosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in miceMuscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaTargeting glutamate synapses in schizophreniaM4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsMolecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic propertiesIncreased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice.Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.G protein-coupled receptors in cardiac biology: old and new receptorsAllosteric Modulation of Muscarinic Acetylcholine Receptors.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.Development of allosteric modulators of GPCRs for treatment of CNS disordersOpportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.Crystal structures of the M1 and M4 muscarinic acetylcholine receptorsAllosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophreniaImpact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's DiseaseDiscovery of Small-Molecule Modulators of the Human Y4 ReceptorDevelopment of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsMuscarinic receptors as model targets and antitargets for structure-based ligand discovery.The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtypeRole of the cholinergic system in the pathology and treatment of schizophrenia.Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.
P2860
Q24605472-083ECA81-58B8-4076-A4C6-477868E19C19Q24608616-F10E5DDD-9E98-4EE5-897C-BD0276FEA085Q24633877-8201E8C4-A15E-4AC0-8318-78D797401373Q24645678-6B891461-A17B-45A9-8920-AA6B74751286Q24657785-2569315B-C99C-4C2E-ADE3-4138BCE8DF5DQ24657902-5D07B5FE-944F-4FB2-A97D-0038D84C9478Q28081112-9B456D1A-EF2F-43FB-AA5B-51B284A58C65Q28253233-6998E070-A98E-4696-A4F9-5A1A914C1215Q28603221-243602C9-1969-4221-8383-94AE8E29ACC2Q30388923-4D399678-F487-4D0C-906D-4CDF8771E972Q30406145-9E6EBE6D-F3EC-4C4C-992D-CAC75A7B8DC1Q30410518-7DDA2AF4-1CB2-4D16-ABD2-BD6CB13A0837Q30444290-1D4F36E4-5F57-46CB-9CBA-74079165CC91Q30459624-41EBDFD0-686C-4598-83FF-4CB8500B319CQ30460392-5E26E477-83A7-4336-AED6-F26996B2E779Q30467341-BFF06B3F-CF72-4539-B6F5-7152BAC5CD17Q30473410-401D7DD0-0221-46D6-9457-B7F22FCFE725Q30474039-074913D7-2AB0-439F-9C88-C9356EF9AB08Q30486707-37EB6261-D24C-498D-8C45-C9EF5E2E0FB0Q30498538-08AF0FAD-272C-4685-8886-7B4505F45E17Q30566770-3E7B8D6A-0D87-4DA6-845E-7F1083B53362Q30830269-621896F4-93EA-47F9-8884-1F8FC73D486DQ33639685-951A32A3-F1C5-4656-BC50-DD09F70A24CDQ33664703-F5EACF8B-EF52-4CBC-A226-E31CE7914B66Q33890786-7AA3248A-B95C-430C-846B-5A39F2959A4FQ33911197-82B21DA3-B37A-44CB-9552-39B3BB207CDFQ34373958-C4258BE1-454C-4982-874D-E001217FF4A0Q34399823-93B891D9-B3A5-4DB4-93FE-AD2BD22415C5Q34517431-967D5437-9D76-4767-A81B-EBA43ED141F1Q34660626-896EA3FA-D6CD-4D0A-931D-5576D1A07FEDQ34672123-5955513A-BC50-4F9C-BB5A-C82846899974Q35614156-3F6DF9B0-6B35-4C29-9C14-BB4AA80EA6EFQ35789730-B9E87E42-365B-4015-A2AA-D50E6EB93784Q36050350-F8B4AE7A-61EE-4E54-A1AA-569EA2B0D71CQ37025888-2A280A23-A47B-4E61-8A4C-B18D74608B4EQ37183072-9C6C25BE-81CA-4D2B-A104-2F3531AC0E98Q37193147-DE120DD2-7CD5-4FFB-B6D0-A535D0165FA3Q37309784-80AF4167-D51A-4976-B815-538A4755533FQ37356496-1812D938-499A-4F9C-A730-1CEF3B32F07FQ37360436-85541936-1475-4A92-96E3-526A645C3F76
P2860
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Allosteric modulation of the m ...... oach to treating schizophrenia
@nl
Allosteric modulation of the m ...... ach to treating schizophrenia.
@ast
Allosteric modulation of the m ...... ach to treating schizophrenia.
@en
type
label
Allosteric modulation of the m ...... oach to treating schizophrenia
@nl
Allosteric modulation of the m ...... ach to treating schizophrenia.
@ast
Allosteric modulation of the m ...... ach to treating schizophrenia.
@en
prefLabel
Allosteric modulation of the m ...... oach to treating schizophrenia
@nl
Allosteric modulation of the m ...... ach to treating schizophrenia.
@ast
Allosteric modulation of the m ...... ach to treating schizophrenia.
@en
P2093
P2860
P3181
P356
P1476
Allosteric modulation of the m ...... ach to treating schizophrenia.
@en
P2093
A Christopoulos
C C Felder
D L McKinzie
F P Bymaster
J M Witkin
N J M Birdsall
R C Thompson
S Lazareno
S N Mitchell
P2860
P304
10978-10983
P3181
P356
10.1073/PNAS.0800567105
P407
P577
2008-08-04T00:00:00Z